Genentech's Hopes For Avastin In Breast Cancer May Rest With New ODAC Members
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA presiding officer Karen Midthun again rebuffs the company's request to convene experts other than the Oncologic Drugs Advisory Committee, but notes that new members are expected to join the panel before the June 28-29 hearing on withdrawing bevacizumab's accelerated approval.